Open AccessCYP 2C19 and ABCB 1 genetic polymorphisms correlate with the recurrence of ischemic cardiovascular adverse events after clopidogrel treatment
Author(s) -
Hou Xumin,
Han Wenzheng,
Gan Qian,
Liu Yuan,
Fang Weiyi
Publication year - 2018
Publication title -
journal of clinical laboratory analysis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.536
H-Index - 50
eISSN - 1098-2825
pISSN - 0887-8013
DOI - 10.1002/jcla.22369
Subject(s) - clopidogrel , medicine , cyp2c19 , conventional pci , adverse effect , acute coronary syndrome , incidence (geometry) , cardiology , pharmacology , aspirin , myocardial infarction , cytochrome p450 , metabolism , physics , optics
Background This study was aimed to investigate the correlation between CYP 2C19 and ABCB 1 polymorphisms and the recurrence of ischemic cardiovascular adverse events in patients with coronary artery disease treated with clopidogrel. Methods A total of 168 patients with coronary heart disease who underwent PCI operation and received clopidogrel treatment were enrolled. Dual antiplatelet therapy was applied to the treatment of patients for 2 years. Thromboelastography was used to test the efficiency of blood coagulation. Polymerase chain reaction ( PCR ) was used to detect CYP 2C19 and ABCB 1 3435 CT polymorphisms. One‐year follow‐up visit was carried out to record the incidence of cardiovascular adverse events after drug‐eluting stent implantation was inset. Results Follow‐up visit results suggested that the patients with high on‐treatment platelet reactivity ( HPR ) had a higher recurrence rate of cardiovascular adverse events after PCI operation and clopidogrel treatment. Gene polymorphism testing results indicated that patients with CYP 2C19*3 had a significantly higher incidence of HPR , whereas CYP 2C19*2 and ABCB 1 3435 CT were not significantly correlated with HPR . Multivariable logistic regression analysis showed that CYP 2C19*3 might be an independent predictive factor of post‐ PCI HPR . In addition, CYP 2C19*3 as well as post‐ PCI HPR could function as independent predictive factors of cardiovascular adverse events. Conclusion CYP 2C19 * 3 polymorphism could be an important predictive factor of HPR and ischemic cardiovascular adverse events after clopidogrel treatment.